Cargando…

A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer

We have evaluated the efficacy and safety of cetuximab plus FOLFIRI for irinotecan and oxaliplatin-refractory colorectal cancers. From September 2004 to February 2006, 31 patients with metastatic colorectal cancer were treated with cetuximab (400 mg/m(2) intravenously [IV] over 2 hr on day 1 followe...

Descripción completa

Detalles Bibliográficos
Autores principales: Koo, Dong Hoe, Lee, Jae-Lyun, Kim, Tae Won, Chang, Heung Moon, Ryu, Min-Hee, Lee, Sung Sook, Kim, Min Kyoung, Sym, Sun Jin, Lee, Jung Shin, Kang, Yoon-Koo
Formato: Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694394/
https://www.ncbi.nlm.nih.gov/pubmed/17923763
http://dx.doi.org/10.3346/jkms.2007.22.S.S98
_version_ 1782168086199140352
author Koo, Dong Hoe
Lee, Jae-Lyun
Kim, Tae Won
Chang, Heung Moon
Ryu, Min-Hee
Lee, Sung Sook
Kim, Min Kyoung
Sym, Sun Jin
Lee, Jung Shin
Kang, Yoon-Koo
author_facet Koo, Dong Hoe
Lee, Jae-Lyun
Kim, Tae Won
Chang, Heung Moon
Ryu, Min-Hee
Lee, Sung Sook
Kim, Min Kyoung
Sym, Sun Jin
Lee, Jung Shin
Kang, Yoon-Koo
author_sort Koo, Dong Hoe
collection PubMed
description We have evaluated the efficacy and safety of cetuximab plus FOLFIRI for irinotecan and oxaliplatin-refractory colorectal cancers. From September 2004 to February 2006, 31 patients with metastatic colorectal cancer were treated with cetuximab (400 mg/m(2) intravenously [IV] over 2 hr on day 1 followed by weekly 1-hr infusions of 250 mg/m(2)) plus bi-weekly FOLFIRI (irinotecan 150 mg/m(2) IV over 90 min, and leucovorin 100 mg/m(2) IV over 2 hr, followed by 5-FU 400 mg/m(2) IV bolus on day 1, and followed by 5-FU 2,400 mg/m(2) by continuous IV over 46 hrs). Patients received a median of four cycles (range: 1-23). Eight (25.8%) patients had confirmed partial responses and 10 (32.2%) had stable disease. After a median follow-up of 13.2 months for surviving patients, the median time to progression was 2.9 months, the median duration of response was 5.4 months, and the median overall survival was 10.9 months. Skin toxicity was observed in 25 patients (80.4%) including grade 3 in 6 patients (19.4%). Other common non-hematologic toxicities of all grades were mucositis (32.3%), asthenia (22.6%), diarrhea (12.9%), and paronychial cracking (12.9%). The combination of cetuximab with FOLFIRI was effective and tolerable in colorectal cancer patients heavily pretreated with a number of chemotherapy regimens.
format Text
id pubmed-2694394
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher The Korean Academy of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-26943942009-06-11 A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer Koo, Dong Hoe Lee, Jae-Lyun Kim, Tae Won Chang, Heung Moon Ryu, Min-Hee Lee, Sung Sook Kim, Min Kyoung Sym, Sun Jin Lee, Jung Shin Kang, Yoon-Koo J Korean Med Sci Original Article We have evaluated the efficacy and safety of cetuximab plus FOLFIRI for irinotecan and oxaliplatin-refractory colorectal cancers. From September 2004 to February 2006, 31 patients with metastatic colorectal cancer were treated with cetuximab (400 mg/m(2) intravenously [IV] over 2 hr on day 1 followed by weekly 1-hr infusions of 250 mg/m(2)) plus bi-weekly FOLFIRI (irinotecan 150 mg/m(2) IV over 90 min, and leucovorin 100 mg/m(2) IV over 2 hr, followed by 5-FU 400 mg/m(2) IV bolus on day 1, and followed by 5-FU 2,400 mg/m(2) by continuous IV over 46 hrs). Patients received a median of four cycles (range: 1-23). Eight (25.8%) patients had confirmed partial responses and 10 (32.2%) had stable disease. After a median follow-up of 13.2 months for surviving patients, the median time to progression was 2.9 months, the median duration of response was 5.4 months, and the median overall survival was 10.9 months. Skin toxicity was observed in 25 patients (80.4%) including grade 3 in 6 patients (19.4%). Other common non-hematologic toxicities of all grades were mucositis (32.3%), asthenia (22.6%), diarrhea (12.9%), and paronychial cracking (12.9%). The combination of cetuximab with FOLFIRI was effective and tolerable in colorectal cancer patients heavily pretreated with a number of chemotherapy regimens. The Korean Academy of Medical Sciences 2007-09 2007-09-30 /pmc/articles/PMC2694394/ /pubmed/17923763 http://dx.doi.org/10.3346/jkms.2007.22.S.S98 Text en Copyright © 2007 The Korean Academy of Medical Sciences http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Koo, Dong Hoe
Lee, Jae-Lyun
Kim, Tae Won
Chang, Heung Moon
Ryu, Min-Hee
Lee, Sung Sook
Kim, Min Kyoung
Sym, Sun Jin
Lee, Jung Shin
Kang, Yoon-Koo
A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer
title A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer
title_full A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer
title_fullStr A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer
title_full_unstemmed A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer
title_short A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer
title_sort phase ii study of cetuximab (erbitux®) plus folfiri for irinotecan and oxaliplatin-refractory metastatic colorectal cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694394/
https://www.ncbi.nlm.nih.gov/pubmed/17923763
http://dx.doi.org/10.3346/jkms.2007.22.S.S98
work_keys_str_mv AT koodonghoe aphaseiistudyofcetuximaberbituxplusfolfiriforirinotecanandoxaliplatinrefractorymetastaticcolorectalcancer
AT leejaelyun aphaseiistudyofcetuximaberbituxplusfolfiriforirinotecanandoxaliplatinrefractorymetastaticcolorectalcancer
AT kimtaewon aphaseiistudyofcetuximaberbituxplusfolfiriforirinotecanandoxaliplatinrefractorymetastaticcolorectalcancer
AT changheungmoon aphaseiistudyofcetuximaberbituxplusfolfiriforirinotecanandoxaliplatinrefractorymetastaticcolorectalcancer
AT ryuminhee aphaseiistudyofcetuximaberbituxplusfolfiriforirinotecanandoxaliplatinrefractorymetastaticcolorectalcancer
AT leesungsook aphaseiistudyofcetuximaberbituxplusfolfiriforirinotecanandoxaliplatinrefractorymetastaticcolorectalcancer
AT kimminkyoung aphaseiistudyofcetuximaberbituxplusfolfiriforirinotecanandoxaliplatinrefractorymetastaticcolorectalcancer
AT symsunjin aphaseiistudyofcetuximaberbituxplusfolfiriforirinotecanandoxaliplatinrefractorymetastaticcolorectalcancer
AT leejungshin aphaseiistudyofcetuximaberbituxplusfolfiriforirinotecanandoxaliplatinrefractorymetastaticcolorectalcancer
AT kangyoonkoo aphaseiistudyofcetuximaberbituxplusfolfiriforirinotecanandoxaliplatinrefractorymetastaticcolorectalcancer
AT koodonghoe phaseiistudyofcetuximaberbituxplusfolfiriforirinotecanandoxaliplatinrefractorymetastaticcolorectalcancer
AT leejaelyun phaseiistudyofcetuximaberbituxplusfolfiriforirinotecanandoxaliplatinrefractorymetastaticcolorectalcancer
AT kimtaewon phaseiistudyofcetuximaberbituxplusfolfiriforirinotecanandoxaliplatinrefractorymetastaticcolorectalcancer
AT changheungmoon phaseiistudyofcetuximaberbituxplusfolfiriforirinotecanandoxaliplatinrefractorymetastaticcolorectalcancer
AT ryuminhee phaseiistudyofcetuximaberbituxplusfolfiriforirinotecanandoxaliplatinrefractorymetastaticcolorectalcancer
AT leesungsook phaseiistudyofcetuximaberbituxplusfolfiriforirinotecanandoxaliplatinrefractorymetastaticcolorectalcancer
AT kimminkyoung phaseiistudyofcetuximaberbituxplusfolfiriforirinotecanandoxaliplatinrefractorymetastaticcolorectalcancer
AT symsunjin phaseiistudyofcetuximaberbituxplusfolfiriforirinotecanandoxaliplatinrefractorymetastaticcolorectalcancer
AT leejungshin phaseiistudyofcetuximaberbituxplusfolfiriforirinotecanandoxaliplatinrefractorymetastaticcolorectalcancer
AT kangyoonkoo phaseiistudyofcetuximaberbituxplusfolfiriforirinotecanandoxaliplatinrefractorymetastaticcolorectalcancer